Literature DB >> 11139726

[Pharmaco-epidemiological study on the prophylactic treatment of migraine. National inquiry on attitude to prescription practices by primary care physicians and neurologists in Franceø].

M Lantéri-Minet1, H Alchaar, G Besson, F Billé-Turc, J Bouillat, F Brudon, A Donnet, P Galletti, M Maitre, Y Moene, G Rambaud, C Rostini, J Valance, J L Gastaut.   

Abstract

A pharmacoepidemiological survey was conducted in order to understand the pattern of migraine prophylactic drug utilization by French physicians. Neurologists and primary care physicians completed a phone-mail-phone questionnaire which inquired about migraine prophylactic treatment. French neurologists and PCP made the same use of migraine prophylaxis in terms of indication, time interval between treatment onset and evaluation, and duration. The two most commonly chosen migraine prophylactic agents were dihydroergotamine and beta-blockers. This study also showed the importance of considering quality of life to evaluate efficacy of migraine prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11139726

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  4 in total

1.  The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.

Authors:  André Pradalier; Michel Lantéri-Minet; Gilles Géraud; Hervé Allain; Christian Lucas; Antonio Delgado
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Dihydroergotamine and its metabolite, 8'-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brain.

Authors:  N Hanoun; F Saurini; L Lanfumey; M Hamon; S Bourgoin
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

3.  Knowledge, Attitudes, and Management of General Practitioners of the Hospital Districts of Ouagadougou about Migraine (Burkina Faso).

Authors:  A A Dabilgou; A Dravé; J M A Kyelem; A Zoma; C Napon; A Millogo; K Karfo; J Kaboré
Journal:  Pain Res Manag       Date:  2021-11-18       Impact factor: 3.037

4.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.